Suppr超能文献

脂蛋白(a)和风险加权载脂蛋白 B:一种新的动脉粥样硬化风险指标。

Lipoprotein(a) and risk-weighted apolipoprotein B: a novel metric for atherogenic risk.

机构信息

Cardiology Department, Ramsay Santé, Médipôle Lyon-Villeurbanne, 158 rue Léon Blum, Villeurbanne, 69100, France.

Université Claude Bernard Lyon 1, University College of General Medicine, 8 Avenue Rockefeller, Lyon, 69008, France.

出版信息

Lipids Health Dis. 2024 Sep 27;23(1):316. doi: 10.1186/s12944-024-02307-6.

Abstract

BACKGROUND

Retention of apolipoprotein B (apoB)-containing lipoproteins within the arterial wall plays a major causal role in atherosclerotic cardiovascular disease (ASCVD). There is a single apoB molecule in all apoB-containing lipoproteins. Therefore, quantitation of apoB directly estimates the number of atherogenic particles in plasma. ApoB is the preferred measurement to refine the estimate of ASCVD risk. Low-density lipoprotein (LDL) particles are by far the most abundant apoB-containing particles. In patients with elevated lipoprotein(a) (Lp(a)), apoB may considerably underestimate risk because Mendelian randomization studies have shown that the atherogenicity of Lp(a) is approximately 7-fold greater than that of LDL on a per apoB particle basis. In subjects with increased Lp(a), the association between LDL-cholesterol and incident CHD (coronary heart disease) is increased, but the association between apoB and incident CHD is diminished or even lost. Thus, there is a need to understand the mechanisms of Lp(a), LDL-cholesterol and apoB-related CHD risk and to provide clinicians with a simple practical tool to address these complex and variable relationships. How can we understand a patient's overall lipid-driven atherogenic risk? What proportion of this risk does apoB capture? What proportion of this risk do Lp(a) particles carry? To answer these questions, we created a novel metric of atherogenic risk: risk-weighted apolipoprotein B.

METHODS

In nmol/L: Risk-weighted apoB = apoB - Lp(a) + Lp(a) x 7 = apoB + Lp(a) x 6. Proportion of risk captured by apoB = apoB divided by risk-weighted apoB. Proportion of risk carried by Lp(a) = Lp(a) × 7 divided by risk-weighted apoB.

RESULTS

Risk-weighted apoB agrees with risk estimation from large epidemiological studies and from several Mendelian randomization studies.

CONCLUSIONS

ApoB considerably underestimates risk in individuals with high Lp(a) levels. The association between apoB and incident CHD is diminished or even lost. These phenomena can be overcome and explained by risk-weighted apoB.

摘要

背景

载脂蛋白 B (apoB) 所含脂蛋白在动脉壁内的滞留,在动脉粥样硬化性心血管疾病 (ASCVD) 中起着主要的因果作用。所有载脂蛋白 B 所含的脂蛋白中都有一个 apoB 分子。因此,apoB 的定量直接估计了血浆中致动脉粥样硬化颗粒的数量。apoB 是改善 ASCVD 风险估计的首选指标。低密度脂蛋白 (LDL) 颗粒是迄今为止最丰富的载 apoB 颗粒。在脂蛋白(a) (Lp(a)) 升高的患者中,apoB 可能会大大低估风险,因为孟德尔随机化研究表明,基于每一个 apoB 颗粒,Lp(a) 的致动脉粥样硬化作用大约是 LDL 的 7 倍。在 Lp(a) 升高的受试者中,LDL-胆固醇与冠心病 (CHD) 事件之间的相关性增加,但 apoB 与 CHD 事件之间的相关性降低甚至消失。因此,需要了解 Lp(a)、LDL-胆固醇和 apoB 相关的 CHD 风险的机制,并为临床医生提供一个简单实用的工具来解决这些复杂和可变的关系。我们如何理解患者的整体脂质驱动的致动脉粥样硬化风险?apoB 能捕获多少风险?Lp(a) 颗粒携带多少风险?为了回答这些问题,我们创建了一种新的致动脉粥样硬化风险度量:风险加权载脂蛋白 B。

方法

以 nmol/L 表示:风险加权 apoB=apoB-Lp(a)+Lp(a)x7=apoB+Lp(a)x6。apoB 捕获的风险比例=apoB 除以风险加权 apoB。Lp(a) 携带的风险比例=Lp(a)x7 除以风险加权 apoB。

结果

风险加权 apoB 与大型流行病学研究和多项孟德尔随机化研究的风险估计一致。

结论

apoB 在 Lp(a) 水平较高的个体中大大低估了风险。apoB 与冠心病事件之间的相关性降低甚至消失。这些现象可以通过风险加权 apoB 来克服和解释。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c68c/11437815/4933dd7cfadf/12944_2024_2307_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验